Top

Published in:

01-09-2005 | Drug and Profile Reports

Cinacalcet hydrochloride: profile report

Published in: Drugs & Therapy Perspectives | Issue 9/2005

Excerpt

Secondary hyperparathyroidism (HPT), a frequent complication associated with chronic kidney disease (CKD), is associated by elevations in circulating parathyroid hormone (PTH), excessive parathyroid gland hyperplasia, abnormalities in bone mineral metabolism and significant morbidity and mortality.[1] Parathyroid carcinoma is also associated with markedly elevated serum calcium and PTH levels and has limited treatment options.[1] …

The use of trade names is for identification purposes only and does not imply endorsement.

Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs 2005; 65(2): 271–81PubMedCrossRef

Moe SM. Cinacalcet hydrochloride: a viewpoint. Drugs 2005; 65(2): 282PubMedCrossRef

Ureña Torres P. Cinacalcet hydrochloride: a viewpoint. Drugs 2005; 65(2): 282–3PubMedCrossRef

Amgen Inc. Cinacalcet (Sensipar®) US prescribing information [online]. Available from URL: http://www.sensipar.com [Accessed 2004 May 5]

Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 Apr 8; 350(15): 1516–25PubMedCrossRef

Goodman WG, Fadda GZ, Finkelstein FO, et al. Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (HPT) [abstract no. SA-P0741]. J Am Soc Nephrol 2003; 14 Suppl.: 460A

Lindberg JS, Culleton B, Wong G, et al. Phase 3 experience with cinacalcet HCl in hemodialysis (HD) and peritoneal dialysis (PD) patients with secondary HPT [abstract no. SA-P0752]. J Am Soc Nephrol 2003; 14 Suppl.: 463A

Silverberg SJ, Fairman C, Bilezikian JP, et al. Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma [abstract no. SA495]. J Bone Miner Res 2004; 19Suppl. 1: S103

Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4): 607–17PubMedCrossRef

10.

Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 64: 245–52CrossRef

Title: Cinacalcet hydrochloride: profile report
Publication date: 01-09-2005
Publisher: Springer International Publishing
Published in: Drugs & Therapy Perspectives / Issue 9/2005
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.2165/00042310-200521090-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cinacalcet hydrochloride: profile report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2005

Dosing errors appear to be the most common type of medication error in paediatric patients

First reports of serious adverse drug reactions in recent weeks

Spot the differences between types of folliculitis before initiating treatment

Avoid even normal consumption of grapefruit juice if potential interaction with oral cardiovascular drugs

Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus

New in the marketplace